Buy & Sell Under Armour Inc Class A (UAA) – Under Armour Inc Class A Price Today
Aura AI Summary
Key Stats
- $2.47BMarket Cap
- Consumer CyclicalSector
- -30.57%3M Drawdown
- $4.10BEnterprise Value
- -Dividend Yield
- 5% Buy | 95% SellTrading Activity
- 91 daysTypical Hold Time
Under Armour Inc Class A (UAA) is currently valued at a market capitalization of $2.47B, with an enterprise value of $4.10B. Over the past 52 weeks, Under Armour Inc Class A has traded between a low of $4.17 and a high of $8.14, highlighting its annual price range. Over the past three months, Under Armour Inc Class A has recorded a drawdown of -30.57%, reflecting recent price volatility. On average, investors hold Under Armour Inc Class A for approximately 91 days, indicating typical investor behavior on the platform.
About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Most Recent News
Exicure resolves Nasdaq filing delay, regains compliance after late 10-Q submission
Exicure, Inc. received a Nasdaq notice for delayed filing of its Q1 2026 Form 10-Q due to changes in financial staff and procedures. The company filed the report on May 29, 2026, and believes it has restored compliance with Nasdaq rules. Exicure is c...

Carahsoft hosts GovExperience Summit to advance government digital service and citizen engagement.
Carahsoft Technology Corp. is hosting the Annual GovExperience Summit on June 2, 2026, in Reston, Virginia, focusing on improving government service delivery and customer experience through emerging technologies. The event gathers leaders from federa...

Kuehn Law investigates Vistagen Therapeutics for alleged misrepresentation in clinical trial risks.
Kuehn Law, PLLC is investigating whether Vistagen Therapeutics' officers and directors breached their duties by misrepresenting risks in their Social Anxiety Disorder clinical trials. The lawsuit claims insiders failed to disclose high placebo respon...
